Bio-Techne Corporation

TECH · NasdaqGS · Stock · Healthcare
$72.50
+0.03% today
Delayed price,

What Bio-Techne does

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Key facts

Sector
Healthcare
Industry
Biotechnology
Market cap
$11.37B
P/E (ttm)
62.5
Forward P/E
31.4
Dividend yield
0.44%
Beta
1.29
Profit margin
15.0%
Employees
3,000
Headquarters
Minneapolis, MN, United States
Exchange
NasdaqGS

Performance

1 Month
+0.2%
3 Months
+0.5%
6 Months
+22.4%
1 Year
+17.2%
5 Years
-38.6%
$43.2052-week range$72.69
Biggest setback — last 12 months
-36.9%
12 Jan 2026 → 11 May 2026
Fell from $68.67 to $43.30 — its sharpest sustained decline this year.
Biggest run-up — last 12 months
+67.7%
11 May 2026 → 21 Sept 2026
Ran from $43.30 to $72.61 — its strongest sustained advance this year.

Price outlook — trend & volatility model

▲ Trend: Uptrend
Price is above its 20-, 50- and 200-day averages, each stacked above the next — a classic technical uptrend structure.
HorizonBear case (−1σ)Base caseBull case (+1σ)
1 Month$66.99 (-7.6%)$72.50$78.47 (+8.2%)
3 Months$63.22 (-12.8%)$72.50$83.14 (+14.7%)
6 Months$59.73 (-17.6%)$72.50$88.00 (+21.4%)
12 Months$55.12 (-24.0%)$72.50$95.35 (+31.5%)
Statistical, not machine-learning: a random-walk (no assumed drift) volatility model built from this ticker's own realized price history, plus a purely descriptive moving-average trend read. Illustrative only — not a price target and not financial advice. The bear and bull cases sit one standard deviation (1σ) below and above today's price, a range that covers about 68% of the outcomes the model treats as plausible, not a 68% chance of either case. Annualized volatility used: 27.4%, blended from this ticker's own 3-month and 1-year realized price history. Base case is deliberately flat — this quantifies a possible range, not a directional prediction. See the full model, including wider (≈95%) bands →

Comparable companies

Recent headlines

Recent insider activity

Sold 21,502 shares at $72.51 — HIGGINS JOHN L, Director · 2026-09-30
Sold 21,499 shares at $72.55 — BAUMGARTNER ROBERT V, Director · 2026-09-24
Acquired 29,776 shares — Bohnen Shane, SVP - General Counsel · 2026-08-19
Acquired 151,172 shares — Kelderman Kim, Chief Executive Officer · 2026-08-19
Acquired 58,897 shares — Hippel James, CFO · 2026-08-19
Source: SEC Form 4 filings. An "acquired" entry with no price is typically a stock award or option exercise rather than an open-market purchase. Search all insider trades →

Learn the basics

Prices and company data are delayed reference figures from public sources (Yahoo Finance, SEC EDGAR) and may be inaccurate or out of date. This page is informational only — it is not investment advice or a recommendation to buy or sell any security. Past performance does not indicate future results.